MMJ PhytoTech Limited announced that it has received results from the first 10 patients who participated in the Phase 2 clinical trial undertaken by MMJ's wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Ltd. PTL's Phase 2 open label clinical trial is aimed at measuring safety and efficacy of Satipharm CBD capsules for reducing seizure frequency in children with refractory, or treatment-resistant epilepsy. Satipharm CBD capsules are a proprietary oral formulation developed using the Gelpell-CBDTM product technology. Satipharm CBD capsules reduced monthly seizure frequency in the treatment-resistant children when added to current medications. The treatment was generally well tolerated, with a safety profile consistent with prior experience. Promising evidence of efficacy has been reported. In 6 patients a reduction of 59-91% in mean monthly seizure frequency was observed following 12 weeks of treatment. The median reduction was -79.5% in the 12-week treatment period compared to the 4-week observation period.